Ask AI
Myasthenia Gravis Targeted Treatment

CE / CME

Mechanism Matters: The Future of Targeted Treatments in Myasthenia Gravis

Nurse Practitioners/Nurses: 0.50 Nursing contact hour, including 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 26, 2026

Expiration: May 25, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Gil I. Wolfe, MD, FAAN, discusses the evolving role of targeted treatments in generalized myasthenia gravis (gMG), with a focus on C5 inhibitors and FcRn inhibitors, including emerging clinical trial data, mechanism-based treatment selection, safety considerations, dosing and administration logistics, and patient selection factors.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

How many people with MG do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following best summarizes recent and emerging clinical trial evidence for targeted C5 inhibitor and FcRn inhibitor strategies in gMG?

A 54-year-old adult with AChR antibody-positive gMG has persistent functional symptoms despite standard therapy. The patient is considering targeted therapy and asks how C5 inhibitors and FcRn inhibitors differ in practical clinical use.

Which of the following is the most accurate counseling statement?